Takeda Pharmaceutical Company Limited

Takeda's prescription-based revenues carry recurring characteristics but are subject to structural LOE cliffs: VYVANSE lost exclusivity in August 2023, driving a 32.1% CER decline in the Neuroscience segment through FY2025. Growth and Launch Products grew 6.7% at constant exchange rates in the first nine months of FY2025 and now represent over 50% of total revenue, providing partial offset but with a newer, less-proven track record.

Revenue is distributed across four therapeutic areas: GI (led by Entyvio), Rare Diseases, Oncology, and Neuroscience, with no single product dominating since Vyvanse LOE reduced Neuroscience's contribution. The rare disease franchise and Entyvio together anchor the business across genuinely different clinical end markets. All segments reside within biopharmaceuticals, limiting cross-sector diversification.

The United States accounts for over 50% of total revenue, with Japan contributing approximately 20% and Europe and Canada roughly another 20%. The US-heavy exposure concentrates Takeda to PBM dynamics, formulary access decisions, and US drug-pricing policy. Meaningful presence in Japan and Europe prevents a single-country characterization, but no region approaches the US in revenue contribution.

Specialty pharmaceutical operations require heavy R&D investment and per-product commercialization infrastructure, limiting operating leverage across the portfolio. Revenue was broadly flat in absolute terms from FY2021 through FY2024, and core operating profit margins held at roughly 25% of total revenue as pipeline investment and LOE headwinds offset scale gains in faster-growing segments.

Entyvio (ulcerative colitis and Crohn's disease), TAKHZYRO (hereditary angioedema), and ELAPRASE (Hunter syndrome) address life-threatening or debilitating conditions where discontinuation carries serious clinical risk, providing above-average revenue stickiness. The GI and rare disease biologics franchise anchors the portfolio in mission-critical therapy, though older small-molecule products remain subject to LOE-driven volume loss.